Publications by authors named "E Kremmer"

Epstein-Barr virus nuclear antigen 1 (EBNA1) contains two arginine-glycine (RG) repeats that contain symmetric/asymmetric dimethylarginine (SDMA/ADMA) and monomethylarginine (MMA) residues. We generated mouse monoclonal antibodies directed against a monomethylated GRGRGG-containing repeat located between amino acids 328 and 377 of EBNA1. In addition to detecting MMA-modified EBNA1, we also had the goal of identifying cellular proteins that bind to MMA-modified EBNA1 in EBV-positive Raji cells.

View Article and Find Full Text PDF

Introduction: Oxysterol-binding protein (OSBP) is known for its crucial role in lipid transport, facilitating cholesterol exchange between the Golgi apparatus and endoplasmic reticulum membranes. Despite its established function in cellular processes, its involvement in coronavirus replication remains unclear.

Methods: In this study, we investigated the role of OSBP in coronavirus replication and explored the potential of a novel OSBP-binding compound, ZJ-1, as an antiviral agent against coronaviruses, including SARS-CoV-2.

View Article and Find Full Text PDF

Innate immune responses are linked to key metabolic pathways, yet the proximal signaling events that connect these systems remain poorly understood. Here we show that phosphofructokinase 1, liver type (PFKL), a rate-limiting enzyme of glycolysis, is phosphorylated at Ser775 in macrophages following several innate stimuli. This phosphorylation increases the catalytic activity of PFKL, as shown by biochemical assays and glycolysis monitoring in cells expressing phosphorylation-defective PFKL variants.

View Article and Find Full Text PDF
Article Synopsis
  • FLT3 is a protein that is often overexpressed or mutated in acute myeloid leukemia (AML), making treatment challenging, even with existing therapies like receptor tyrosine kinase inhibitors (TKIs).
  • Researchers developed a new antibody-drug conjugate (ADC) called 20D9-ADC, which effectively targets FLT3 and shows significant cytotoxic effects against various AML cells in lab tests and promising results in animal models.
  • The combination of 20D9-ADC with the TKI midostaurin demonstrated strong effectiveness, suggesting a powerful new treatment strategy for FLT3-ITD-positive AML with reduced side effects.
View Article and Find Full Text PDF